Abstract
BackgroundIn the last decade, the number of new drugs in development for the treatment of systemic lupus erythematosus (SLE) and related indications, e.g., lupus nephritis (LN) has been increasing. Belimumab's...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
